FDA panel rejects testosterone patch for women on safety groundsBMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7479.1363 (Published 09 December 2004) Cite this as: BMJ 2004;329:1363
- Ray Moynihan
- Washington, DC
A panel of advisers to the US Food and Drug Administration last week unanimously rejected an experimental testosterone patch as a treatment for women with sexual difficulties.
Procter & Gamble, global manufacturer of household products, wants to market the patch to women who have become menopausal after ovarian surgery, are currently taking oestrogen, and are said to have a controversial condition—“hypoactive sexual desire disorder.”
The FDA had granted Procter & Gamble a fast track review of the testosterone patch, but the committee's unanimous …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial